Successful ceftolozane‐tazobactam rescue therapy in a child with endocarditis caused by multidrug‐resistant Pseudomonas aeruginosa
暂无分享,去创建一个
P. Brañas | S. Grau | D. Blázquez-Gamero | C. Epalza | Marta Flores | Marta Olmedilla | María Martín-Cazaña
[1] D. Kontoyiannis,et al. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient. , 2016, The Pediatric infectious disease journal.
[2] Christina A. Sutherland,et al. Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes. , 2016, Journal of chromatographic science.
[3] R. Baltimore,et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association , 2015, Circulation.
[4] A. Kwa,et al. Prolonged infusion versus intermittent boluses of β-lactam antibiotics for treatment of acute infections: a meta-analysis. , 2014, International journal of antimicrobial agents.
[5] E. Hershberger,et al. Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam , 2014, Antimicrobial Agents and Chemotherapy.
[6] M. Maciá,et al. Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study , 2011, Antimicrobial Agents and Chemotherapy.
[7] J. Caillon,et al. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. , 2001, The Journal of antimicrobial chemotherapy.
[8] U. Flückiger,et al. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model , 1991, Antimicrobial Agents and Chemotherapy.